PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets
April 12, 2023 17:24 ET
|
PLx Pharma Inc.
SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its...
PLx Pharma Inc. Receives Nasdaq Delisting Notice
April 11, 2023 16:28 ET
|
PLx Pharma Inc.
SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its...
PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update
November 10, 2022 17:00 ET
|
PLx Pharma Inc.
- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade...
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update
October 26, 2022 09:00 ET
|
PLx Pharma Inc.
SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its...
Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels
September 12, 2022 16:30 ET
|
PLx Pharma Inc.
SPARTA, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its...
Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg
August 12, 2022 07:00 ET
|
PLx Pharma Inc.
Results of National Patient Experience Survey Show 95% Satisfaction Rate with VAZALORE 81 mg as Aspirin Therapy Choice FDA-Approved VAZALORE Delivers Fast, Reliable Absorption of Aspirin ...
PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update
August 12, 2022 06:50 ET
|
PLx Pharma Inc.
- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total...
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update
July 27, 2022 08:30 ET
|
PLx Pharma Inc.
SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its...
PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022
June 01, 2022 08:30 ET
|
PLx Pharma Inc.
SPARTA, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its...
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions
May 20, 2022 08:30 ET
|
PLx Pharma Inc.
SPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its...